EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Peak Plasma Concentration (Cmax)/Minimum Inhibitory Concentration (MIC) of bedaquiline and levofloxacin with special attention to the sputum conversion in the treatment of multidrug-resistant tuberculosis in Indonesia

Nina Mariana iD, Anggi Gayatri, Indah Suci Widyahening, Budiman Bela iD, Soedarsono Soedarsono iD, Iin Maemunah, Rosamarlina Rosamarlina, Vivi Setiawaty iD, Vithal Prasad Myneedu iD, Erni Juwita Nelwan, Purwantyastuti Ascobat

PLOS One · 2025

DOI: 10.1371/journal.pone.0336210 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Nina Mariana und 10 weiteren Autor:innen. Beteiligte Einrichtung: Doctoral program in Medical Sciences, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia. Hauptthemen laut MEDLINE: Levofloxacin, Tuberculosis, Multidrug-Resistant, Sputum, Antitubercular Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitas Indonesia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tuberculosis in Indonesia remains a serious public health concern, as the country has the third-largest number of multidrug-resistant tuberculosis (MDR-TB) patients in the world. Bedaquiline and levofloxacin are the primary drug regimen for MDR-TB treatment in Indonesia. This study aimed to investigate whether the Cmax/MIC of bedaquiline and levofloxacin differs between patients with sputum conversion and those without sputum conversion during the first four months of MDR-TB treatment in Indonesia.

Methods

A cohort study was performed in adult patients (18–65 years old) treated with the 18–24-month oral regimen. Patients were excluded if they were pregnant or HIV positive, with uncontrolled diabetes, or had any of the following severe conditions: cancer, digestive, cardiovascular system disorders, hepatic, or renal problems. Two blood samples were collected to measure the plasma concentrations of bedaquiline and levofloxacin using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Mycobacterium tuberculosis (Mtb) isolates from patients’ sputum were used to determine the MIC of individual drugs using liquid growth media (MGIT).

Results

Among the 74 patients enrolled, 16 dropped out during the four-month follow-up period. Blood samples were successfully obtained 1–2 hours after drug administration from 48 patients and 4–6 hours after drug administration from 32 patients, which were used for pharmacokinetic analysis. Sputum conversion was detected in 84.5% of patients during four months of the MDR-TB treatment. The mean Cmax/MIC ratio of bedaquiline was higher in the sputum conversion group compared with the non-conversion group (9.10 vs. 1.65, respectively). Meanwhile, a small difference in the Cmax/MIC ratio of levofloxacin was observed between the sputum conversion group and the non-conversion group; it was not significant (45.64 vs. 41.72, respectively; p = 0.941).

Conclusions

Cmax/MIC of bedaquiline was higher in MDR-TB patients with sputum conversion compared to those without conversion within the first four months of treatment, suggesting a potential relationship between Cmax/MIC of bedaquiline and sputum conversion, which was not seen in the levofloxacin cases. However, the application of clinical practice should be carefully considered and supported by further study in various settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LevofloxacinTuberculosis, Multidrug-ResistantSputumAntitubercular AgentsDiarylquinolinesHumansAdultFemaleMaleIndonesiaMiddle AgedMicrobial Sensitivity TestsAgedAdolescentYoung AdultMycobacterium tuberculosisCohort Studies

Substanzen

LevofloxacinAntitubercular AgentsbedaquilineDiarylquinolines

Autor:innen und Institutionen

  • Doctoral program in Medical Sciences, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
  • Directorate Of Human Resources-Education and Research, National Infectious Disease Center - Sulianti Saroso Hospital, Jakarta, Indonesia.
  • Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
  • Department of Community Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
  • Department of Microbiology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
  • Sub-Pulmonology Department of Internal Medicine, Faculty of Medicine, University of Hang Tuah, Surabaya, Indonesia.

ORCID-Profile: Nina Mariana, Budiman Bela, Soedarsono Soedarsono, Vivi Setiawaty, Vithal Prasad Myneedu

Förderung

  • Universitas Indonesia

Zitieren

APA

Mariana, N., Gayatri, A., Widyahening, I. S., Bela, B., Soedarsono, S., Maemunah, I., Rosamarlina, R., Setiawaty, V., Myneedu, V. P., Nelwan, E. J., & Ascobat, P. (2025). The Peak Plasma Concentration (Cmax)/Minimum Inhibitory Concentration (MIC) of bedaquiline and levofloxacin with special attention to the sputum conversion in the treatment of multidrug-resistant tuberculosis in Indonesia. PLOS One. https://doi.org/10.1371/journal.pone.0336210

Vancouver

Mariana N, Gayatri A, Widyahening IS, Bela B, Soedarsono S, Maemunah I, et al. The Peak Plasma Concentration (Cmax)/Minimum Inhibitory Concentration (MIC) of bedaquiline and levofloxacin with special attention to the sputum conversion in the treatment of multidrug-resistant tuberculosis in Indonesia. PLOS One. 2025. doi:10.1371/journal.pone.0336210

BibTeX
@article{Mariana2025,
  author = {Mariana, Nina and Gayatri, Anggi and Widyahening, Indah Suci and Bela, Budiman and Soedarsono, Soedarsono and Maemunah, Iin and Rosamarlina, Rosamarlina and Setiawaty, Vivi and Myneedu, Vithal Prasad and Nelwan, Erni Juwita and Ascobat, Purwantyastuti},
  title = {The Peak Plasma Concentration (Cmax)/Minimum Inhibitory Concentration (MIC) of bedaquiline and levofloxacin with special attention to the sputum conversion in the treatment of multidrug-resistant tuberculosis in Indonesia},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0336210}
}
Kostenlos starten →